Docstoc

Alzheimer’s disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs Analysis

Document Sample
Alzheimer’s disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs Analysis Powered By Docstoc
					        Renub Research
        www.renub.com
Alzheimer’s Disease Patients & Market
 Worldwide, Future Scenario (2010 –
       2015) & Drugs Analysis




Publisher: Renub Research
Published: June, 2011
Alzheimer’s Disease - Market Overview

Alzheimer’s is a complex disease and there is no single “magic bullet” available in the market
to prevent or cure it. Though many marketed drugs have been approved for Alzheimer’s
disease, but it still remains a significant area of unmet medical need. Clinical success has
proven elusive; however, numerous companies are developing novel treatments. Currently
there’s no cure for Alzheimer’s and its still waiting for its key product. In addition, all current
marketed products are going to be generic in the next five years.


In 2010, there were more than 30 Million people suffering with Alzheimer’s disease but it is
anticipated that by 2015 over 35 Million people worldwide will be suffering from this disease.
Much of this increase will be due to increase in number of people with Alzheimer’s in low and
middle income countries. Since the risk of getting the disease increases with age, the number
of patients with the illness to be found in any community will depend on the proportion of
older people in the group. Traditionally, the developed countries have large proportions of
elderly people, and so they have many cases of Alzheimer’s disease in the community at one
time. However, developing countries are also undergoing a demographic transition so that
more and more persons are surviving to an old age.


Global Alzheimer’s disease has increased manifold and expected to cross US$ 19 Billion by
2015. North America controls more than 50% of the total Alzheimer’s drug market share in
2010. Over the past years, the Alzheimer’s disease market has been flagged with several
drugs into the market. Till last year Aricept was the world best selling drug which lost patent
protection in November 2010, a milestone that will be followed by a rapid loss in sales. But
there are other drugs which has the potential to become blockbuster drug by 2010. Namenda,
Exelon has shown alluring growth in the market and become blockbusters in 2010. Ebixa a
drug of Memantine group is expected to have a Billion dollar market by 2014. Given the
alarming worldwide growth in Alzheimer’s patients, and especially if companies are able to
address major unmet needs, the outlook for the Alzheimer’s disease market is excellent.
Report Details

Renub Research report titled “Alzheimer’s Disease Patients & Market Worldwide, Future
Scenario (2010 – 2015) & Drugs Analysis” studies the Alzheimer’s Disease patients
prevalence worldwide and region wise. The report provides data on the Alzheimer’s Disease
market Worldwide, North America, Europe and Rest of the world.


Alzheimer’s drugs such as Exelon, Aricept, Namenda, Razadyne, Axura, Ebixa, Nootropil,
Prometax, Memac, Eranz market past, present and future scenario has been analyzed in this
report.


Key questions answered in the report?

            Which regions have the highest prevalence of Alzheimer’s Disease diseases today
             and by 2050?
            What is the market share accounted by Alzheimer’s disease drugs in the global
             markets?
            What is the market share accounted by the region in the global market?
            Which drugs have patent expiry and future forecast of drug sales?


Research Highlights

         More than 35 Million people are expected to suffer from Alzheimer’s disease by 2015
          worldwide.
         By 2050, 59 percent of the world’s Alzheimer’s cases will live in Asia.
         Global Alzheimer’s disease market is expected to cross the figure of US$ 19 Billion by
          2015.
         North America is the leading market share taker in the Alzheimer’s disease market.
         Aricept sales is expected to fall after losing its patent in November 2010
         Ebixa, Excelon & Namenda are on the path of becoming the next blockbuster drugs
          after Aricept




© Renub Research                             Page 3 of 18
Key Company Profiles

This section provides business overview and key financial information of the companies listed
below: Forest Laboratories, Eisai, H. Lundbeck A/S, Novartis, Merz GmbH & Co. KGaA,
Johnson & Johnson, UCB


Data Sources

Information and data in this report has been collected from various printable and non-
printable sources like Trade Journals, White papers, Online paid databases, News websites,
Government Agencies, Magazines, Newspapers and Trade associations.




© Renub Research                        Page 4 of 18
                                         Published
                                             By

                                 Renub Research
                                     A–116B, Sector–27
                                       Noida – 201301
                        Phone: +91-120-4219-822, 2545-750 (India)
                                   +1-678-3020-700 (USA)
                                  Fax : +91-120-4249-780
                                  Email: info@renub.com
                                      www.renub.com




 © Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs
                                          Analysis
                                   Renub Research, 2011
                                         Edition 1.0
                      All rights reserved. This publication is protected
                   by copyright. No part of it may be reproduced, stored
                   in a retrieval system or transmitted, in any form or by
                     any means, electronic mechanical, photocopying,
                     recording or otherwise without the prior written
                                permission of the publishers




© Renub Research                         Page 5 of 18
                                          Table of Contents

1.     Executive Summary

2.     Worldwide Prevalence of Alzheimer’s Patients

     2.1   Total Number of Alzheimer’s Patients

     2.2   Total Number of Early Stage Alzheimer’s Patients

     2.3   Total Number of Late Stage Alzheimer’s Patients

3.     Regional Estimates for Alzheimer’s Patients

     3.1   Africa
       3.1.1      Total Number of Alzheimer’s Patients
       3.1.2      Total Number of Early Stage Alzheimer’s Patients
       3.1.3      Total Number of Late Stage Alzheimer’s Patients

     3.2   Asia
       3.2.1      Total Number of Alzheimer’s Patients
       3.2.2      Total Number of Early Stage Alzheimer’s Patients
       3.2.3      Total Number of Late Stage Alzheimer’s Patients

     3.3   Europe
       3.3.1      Total Number of Alzheimer’s Patients
       3.3.2      Total Number of Early Stage Alzheimer’s Patients
       3.3.3      Total Number Of Late Stage Alzheimer’s Patients

     3.4   Latin America & Caribbean
       3.4.1      Total Number of Alzheimer’s Patients
       3.4.2      Total Number of Early Stage Alzheimer’s Patients
       3.4.3      Total Number of Late Stage Alzheimer’s Patients

     3.5   North America
       3.5.1      Total Number of Alzheimer’s Patients
       3.5.2      Total Number of Early Stage Alzheimer’s Patients
       3.5.3      Total Number of Late Stage Alzheimer’s Patients

     3.6   Oceania
       3.6.1      Total Number of Alzheimer’s Patients
       3.6.2      Total Number of Early Stage Alzheimer’s Patients
       3.6.3      Total Number of Late Stage Alzheimer’s Patients

4.     Worldwide Alzheimer’s Disease Market


© Renub Research                                Page 6 of 18
     4.1      North America Alzheimer’s Disease Market

     4.2      Europe Alzheimer’s Disease Market

     4.3      Rest of the World Alzheimer’s Disease Market

5.     Worldwide – Alzheimer’s Drug Market Share 2008 – 2009

6.     Worldwide – Top 10 Alzheimer’s Drug Brands Market Performance

     6.1      Exelon (Rivastigmine) – Past, Present & Future Forecast

     6.2      Aricept (Donepezil) – Past & Present Market

     6.3      Razadyne (Galantamine) (Past & Present Market)

     6.4      Memantine (Namenda, Ebixa, Axura)
       6.4.1          Namenda (Memantine) – Past, Present & Future Forecast
       6.4.2          Ebixa (Memantine) – Past, Present & Future Forecast
       6.4.3          Axura (Memantine) – Past, Present & Future Forecast

     6.5      Nootropil (Piracetam) – Past, Present & Future Market

     6.6      Prometax (Rivastigmine) – Past, Present & Future Forecast

     6.7      Memac (Donepezil)

     6.8      Eranz (Donepezil)

     6.9      Future Blockbuster Alzheimer’s Drug

7.     Alzheimer’s Disease Deals, 2005 – 2009

8.     Key Drivers of Growth in Global Alzheimer’s Disease Drug Market

     8.1      Aging Population

     8.2      Unmet Medical Needs

     8.3      Future Drugs for Disease Modification in Alzheimer’s Disease

9.     Key Challenges in the Global Alzheimer’s Disease Drug Market

     9.1      Lack of Validated Targets & Lack of Animal Models

     9.2      Barriers in the Design and Implementation of Clinical Trials

     9.3      Barriers in Academia & Regulatory Issues

10.         Key Players in the Alzheimer’s Drug Market

     10.1     Forest Laboratories

     10.2     Eisai


© Renub Research                                   Page 7 of 18
  10.3   H. Lundbeck A/S

  10.4   Novartis

  10.5   Merz GmbH & Co. KGaA

  10.6   Johnson & Johnson

  10.7   UCB




© Renub Research                Page 8 of 18
List of Figures:


Figure 2-1: Worldwide – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 2-2: Worldwide – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 2-3: Worldwide – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3-1: Africa – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3-2: Africa – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3-3: Africa – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3-4: Asia – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3-5: Asia – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3-6: Europe – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3-7: Europe – Number of Patients with Early Stage Alzheimer ’s Disease (Million), 2006 – 2010
Figure 3-8: Europe – Number of Patients with Late Stage Alzheimer ’s Disease (Million), 2006 – 2010
Figure 3-9: Latin America & Caribbean – Number of Patients with Alzheimer’s Disease (Million), 2006 –
     2010
Figure 3-10: Latin America & Caribbean – Number of Patients with Early Stage Alzheimer’s Disease
     (Million), 2006 – 2010
Figure 3-11: Latin America & Caribbean – Number of Patients with Late Stage Alzheimer’s Disease
     (Million), 2006 – 2010
Figure 3-12: North America – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3-13: North America – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 –
     2010
Figure 3-14: North America – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 –
     2010
Figure 3-15: Oceania – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3-16: Oceania – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3-17: Oceania – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 4-1: Worldwide – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
Figure 4-2: Worldwide – Future Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
Figure 4-3: North America – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
Figure 4-4: North America – Future Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
Figure 4-5: Europe – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
Figure 4-6: Europe – Future Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
Figure 4-7: Rest of the World – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
Figure 4-8: Rest of the World – Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
Figure 5-1: Worldwide – Drug Companies Market Share in Alzheimer’s Disease Market (Percent), 2008
Figure 5-2: Worldwide – Drug Companies Market Share in Alzheimer’s Disease Market (Percent), 2009



© Renub Research                              Page 9 of 18
Figure 6-1: Worldwide – Exelon Alzheimer’s Drug Sales (Million US$), 2005 – 2010
Figure 6-2: Worldwide – Future Forecast for Exelon Alzheimer’s Drug Sales (Million US$), 2010 – 2014
Figure 6-3: Worldwide – Aricept Alzheimer’s Drug Sales (Billion US$), 2005 – 2009
Figure 6-4: Worldwide – Razadyne Alzheimer’s Drug Sales (Million US$), 2007 – 2009
Figure 6-5: Worldwide – Namenda Alzheimer’s Drug Sales (Million US$), 2003 – 2010
Figure 6-6: Worldwide – Future Forecast for Namenda Alzheimer’s Drug Sales (Million US$), 2011 – 2015
Figure 6-7: Worldwide – Ebixa Alzheimer’s Drug Sales (Million US$), 2003 – 2010
Figure 6-8: Worldwide – Future Forecast for Ebixa Alzheimer’s Drug Sales (Million US$), 2011 – 2014
Figure 6-9: Worldwide – Axura Alzheimer’s Drug Sales (Million US$), 2003 – 2010
Figure 6-10: Worldwide – Future Forecast for Axura Alzheimer’s Drug Sales (Million US$), 2011 – 2014
Figure 6-11: Worldwide – Nootropil Alzheimer’s Drug Sales (Million US$), 2004 – 2010
Figure 6-12: Worldwide – Future Forecast for Nootropil Alzheimer’s Drug Sales (Million US$), 2011 –
     2014
Figure 6-13: Worldwide – Prometax Alzheimer’s Drug Sales (Million US$), 2007 – 2010
Figure 6-14: Worldwide – Future Forecast for Prometax Alzheimer’s Drug Sales (Million US$), 2011 –
     2012
Figure 6-15: Worldwide – Memac Alzheimer’s Drug Sales (Million US$), 2007 – 2009
Figure 6-16: Worldwide – Eranz Alzheimer’s Drug Sales (Million US$), 2007 – 2009
Figure 8-1: Worldwide – Population Aged 60 or Over: World and Development Regions, 1950, 1975,
     2009, 2025 & 2050
Figure 8-2: Worldwide – Old-Age Dependency Ratio: Major Areas, 2009 & 2050




© Renub Research                             Page 10 of 18
List of Tables:


Table 2-1: Worldwide – Forecast For Number of Patients with Alzheimer’s (Million) 2011 – 2015, 2020,
     2025, 2030, 2035, 2040, 2045, 2050
Table 2-2: Worldwide – Stages of Alzheimer’s Disease
Table 2-3: Worldwide – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million)
     2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 2-4: Worldwide – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million),
     2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-1: Africa – Forecast for Number of Patients with Alzheimer’s Disease (Million), 2011 – 2015,
     2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-2: Africa – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011
     – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-3: Africa – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 –
     2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-4: Asia – Forecast for Number of Patients with Alzheimer’s Disease (Million), 2011 – 2015, 2020,
     2025, 2030, 2035, 2040, 2045, 2050
Table 3-5: Asia – Number of Patients with early stage Alzheimer’s Disease (Million), 2006 – 2010
Table 3-6: Asia – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 –
     2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-7: Asia – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 –
     2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-8: Europe – Forecast for Number of Patients with Alzheimer ’s Disease (Million), 2011 – 2015,
     2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-9: Europe – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011
     – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-10: Europe – Forecast for number of patients with late stage Alzheimer’s Disease (Million), 2011
     – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-11: Latin America & Caribbean – Forecast for Number Of Patients with Alzheimer’s Disease
     (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-12: Latin America & Caribbean – Forecast for Number of Patients with Early Stage Alzheimer’s
     Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-13: Latin America & Caribbean – Forecast for Number of Patients with Late Stage Alzheimer’s
     Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-14: North America – Forecast for Number of Patients with Alzheimer’s Disease (Million), 2011 –
     2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050




© Renub Research                              Page 11 of 18
Table 3-15: North America – Forecast for Number of Patients with Early Stage Alzheimer’s Disease
     (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-16: North America – Forecast for Number of Patients with Late Stage Alzheimer’s Disease
     (Million), 2011 – 2016, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-17: Oceania – Forecast for Number Of Patients with Alzheimer’s Disease (Million), 2011 – 2016,
     2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-18: Oceania – Forecast for Number of Patients with Early Stage Alzheimer’s Disease
     (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3-19: Oceania – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million),
     2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 6-1: Worldwide – Bapineuzumab Drug Future Forecast Sales, (Billion US$), 2016
Table 7-1: Worldwide – Alzheimer’s Disease Deals, 2005 – 2009
Table 8-1: Worldwide – Population Aged 60 or Over, 65 or Over and 80 Or Over By Sex (Thousands):
     World, Major Areas and Regions, 2009
Table 10-1: Forest Laboratories – Key Financials (Million US$), March 2008 – March 2010
Table 10-2: Eisai – Key Financials (Million US$) March 2008 – March 2010
Table 10-3: H. Lundbeck A/S – Key Financials (Million US$), 2007 – 2009
Table 10-4: Novartis – Key Financials (Million US$), 2007 – 2009
Table 10-5: Merz GmbH & Co. KGaA – Key Financials (Euro Million) 2007/08 – 2008/09
Table 10-6: Johnson & Johnson – Key Financials (Million US$) 2007 – 2009
Table 10-7: UCB – Key Financials (Million US$) 2007 – 2009




© Renub Research                             Page 12 of 18
                                       Order Form

Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact
Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780


Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to
info@renub.com


                                             Format

Report Title: Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015)
& Drugs Analysis


       Single User             Hard Copy                 CD – Rom          Global Site License
  (Email from Publisher)     (Mail Delivery)           (Mail Delivery)   (Multiple User License)
         US$ 950                US$ 1,050                   US$ 1,050          US$ 1,700



For ordering this report: Three easy ways to place your order:

1) Order online by Credit Card (Visa, MasterCard, etc.):
http://renub.com/reports/showdetails.aspx?id=42


2) Order by Wire Transfer:
http://renub.com/reports/wiretransfer.aspx?id=42&pid=1146


To pay by Wire Transfer, please, fill in your contact details in the form below:




© Renub Research                            Page 13 of 18
                                          Bank Details

Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th Floor
              Indian Red Cross Building
              1 Red Cross Road
              Opposite Parliament Street
              New Delhi – 110001
              India




                                   Contact Information

First Name:                                  Last Name:
Email:
Job Title:
Company:
Address:
City:
Postal/Zip Code:
Country:
Phone:
Mobile:
Fax:
Report Format:
Your message:




© Renub Research                           Page 14 of 18
3) Order by Check


Please post the check accompanied by this form, to:


Company Address: Renub Research
                   A -116B
                   Sector -27
                   Noida - 201301
                   Uttar Pradesh
                   India
                   Phone: +91-120-421-9822, 424-9780




For free Sample copy report or to view any of our sample work please contact us at
info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)




                                        Follow Us


Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090
LinkedIn: http://www.linkedin.com/company/renub-research
Twitter:   http://twitter.com/RenubResearch




© Renub Research                         Page 15 of 18
                                      Our Partial List of Clients


Redbus                                                         Bain

Becton Dickinson                                               WAKE Technology Services, Inc.

Pfizer                                                         PSS World Medical

Intercell                                                      Relypsa

Sanofi Pasteur                                                 C&K components

Stanford Burgess                                               Konkuk University

Pequot Capital                                                 Resonetics

DMI                                                            Samsung

Transgene S.A.                                                 SEKISUI MEDICAL CO. LTD.

ixia communications                                            Plentyoffish Media INC

Toyota Tsusho Amercia Inc.                                     Arthur D Little Gmbh

National Health Research Institutes                            Morgan Stanley

Abbott Diabetes Care                                           Takeda Pharmaceutical Corporation

Corning Incorporated - Life Sciences                           Hokkai School of Commerce

L.E.K. Consulting GmbH                                         Ministry of Manpower Singapore

Syntiron                                                       GenOmind, LLC.

MediVas LLC                                                    Goldman Sachs & Co

Credit Suisse                                                  NTT Advanced Technology

Dune Medical                                                   Tokyo Womens Medical University

QIAGEN                                                         The Chemo-Sero-Therapeutic Research

Inje University                                                Trade Council of Iceland

Mapp Biopharmaceutical                                         Jpmorgan, Ets Trading

Institute for Information Industry                             GE Healthcare IT

NorDiag ASA                                                    ixia communications
       © Renub Research                        Page 16 of 18
Rep e Inv Medicas SA de

Innogenetics
                                       Disclaimer

 Most of the information available in this report is within the public domain. The submitting
authors or other copyright holders retain rights for reproduction or redistribution. All persons
   reproducing or redistributing this information are expected to adhere to the terms and
constraints invoked by the copyright holder. Such protected material, however, may be used
under the terms of "fair use” as defined in the copyright laws, which generally permit use for
    non-commercial educational purposes such as teaching, research, criticism, and news
                                          reporting.


 With respect to documents available, neither the company nor any of its employees makes
any warranty, express or implied, including the warranties of merchantability and fitness for
    a particular purpose, or assumes any legal liability or responsibility for the accuracy,
completeness, or usefulness of any information, apparatus, product, or process disclosed, or
              represents that its use would not infringe privately owned rights.


  Unless otherwise stated, the copyright, database rights, and similar rights in all material
 published on this manual is solely owned by Renub Research. You are permitted to print or
download extracts from this material for your personal use only. None of this material may be
used for any commercial or public use. No part of this manual or any material appearing may
be reproduced, stored in or transmitted on any other Web site without written permission of
www.renub.com and any payments of a specified fee. Requests to republish any material may
                              be sent to us at info@renub.com.




© Renub Research                          Page 17 of 18
About Us

Renub Research          is a leading Market Research and Information Analysis Company with
centers at Noida India and Roswell USA. We have more than 7 years of experience especially
in   international   Business-to-Business   Researches,     Surveys,   Business   and   Consulting.
Throughout the years we have acquired expertise in most market sectors, including
Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial
Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive,
Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.


Our core team is comprised of an experienced people holding graduate, post graduate and
Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information
Technology, Environmental Science and many more. Our research help make the business
decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We
support many blue chip companies by providing them findings and perspectives across a wide
range of markets. Our research reports offer a blend of information insight, analysis and
forecasting that is essential in today’s ultra-competitive markets.




© Renub Research                            Page 18 of 18

				
DOCUMENT INFO
Description: Report Details Renub Research report titled “Alzheimer’s Disease Patients & Market Worldwide, Future Scenario (2010 – 2015) & Drugs Analysis” studies the Alzheimer’s Disease patients prevalence worldwide and region wise. The report provides data on the Alzheimer’s Disease market Worldwide, North America, Europe and Rest of the world. Alzheimer’s drugs such as Exelon, Aricept, Namenda, Razadyne, Axura, Ebixa, Nootropil, Prometax, Memac, Eranz market past, present and future scenario has been analyzed in this report. Key questions answered in the report? • Which regions have the highest prevalence of Alzheimer’s Disease diseases today and by 2050? • What is the market share accounted by Alzheimer’s disease drugs in the global markets? • What is the market share accounted by the region in the global market? • Which drugs have patent expiry and future forecast of drug sales? Research Highlights • More than 35 Million people are expected to suffer from Alzheimer’s disease by 2015 worldwide. • By 2050, 59 percent of the world’s Alzheimer’s cases will live in Asia. • Global Alzheimer’s disease market is expected to cross the figure of US$ 19 Billion by 2015. • North America is the leading market share taker in the Alzheimer’s disease market. • Aricept sales is expected to fall after losing its patent in November 2010 • Ebixa, Excelon & Namenda are on the path of becoming the next blockbuster drugs after Aricept Key Company Profiles This section provides business overview and key financial information of the companies listed below: Forest Laboratories, Eisai, H. Lundbeck A/S, Novartis, Merz GmbH & Co. KGaA, Johnson & Johnson, UCB Data Sources Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.